Home Journals Articles Updates About
CN
image
收藏切换
A novel vanadium complex VO(p-dmada) inhibits neuroinflammation induced by lipopolysaccharide
收藏切换
PDF
Zhijun Hea, b, Xiaoqian Lia, Huajie Zhanga, Xin Liue, Shuangxue Hana, Anwar Abdurahmana, Liming Shena, Xiubo Dua, c, Nan Li*, a, f, Xiaoda Yang*, d, Qiong Liu*, a, c
Chinese Chemical Letters | 2023, 34(10) : 108236
Less
收藏切换
Chinese Chemical Letters | 2023, 34(10): 108236
• Communication •
A novel vanadium complex VO(p-dmada) inhibits neuroinflammation induced by lipopolysaccharide
Full
Zhijun Hea, b, Xiaoqian Lia, Huajie Zhanga, Xin Liue, Shuangxue Hana, Anwar Abdurahmana, Liming Shena, Xiubo Dua, c, Nan Li*, a, f, Xiaoda Yang*, d, Qiong Liu*, a, c
Affiliations
  • a Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518055, China
  • b National R&D Center for Se-rich Agricultural Products Processing, Hubei Engineering Research Center for Deep Processing of Green Se-rich Agricultural Products, School of Modern Industry for Selenium Science and Engineering, Wuhan Polytechnic University, Wuhan 430023, China
  • c Shenzhen Bay Laboratory, Shenzhen 518055, China
  • d State Key Laboratories of Natural and Biomimetic Drugs, Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • e Department of Pharmacy, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China
  • f Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen 518055, China
Published: 2023-10-15 doi: 10.1016/j.cclet.2023.108236
Outline
收藏切换

Uncontrolled microglial activation is decisively involved in the neuroinflammatory pathogenesis of brain diseases. Consequently, suppression of microglial overactivation appears to be a strategy for the prevention of nerve injury. In this paper, a novel vanadium complex, vanadyl N-(p-N,N-dimethylaminophenylcarbamoylmethyl)iminodiacetate (VO(p-dmada)), was synthesized from vanadyl sulfate and N,N-dimethyl-p-phenylenediamine, which was structurally characterized by Fourier transform infrared spectrum and ESI-MS analysis. The effect of VO(p-dmada) on neuroinflammation was investigated by using the models of lipopolysaccharide (LPS)-induced BV2 microglial cells and BALB/c mice. Our data demonstrated that VO(p-dmada) significantly suppressed microglial activation by downregulating inflammatory mediators and associated proteins, and inactivating nuclear factor-κB (NF-κB) signaling pathway. VO(p-dmada) also upregulated peroxisome proliferator activated receptor gamma (PPARγ) by reducing transglutaminase 2 and heat shock protein 60 expression. Co-treatment with PPARγ antagonist GW9662 significantly impeded the inhibitory effect of VO(p-dmada) on LPS-induced neuroinflammation. These cumulative findings demonstrated that VO(p-dmada) is a potential new drug for the treatment of neuroinflammation-related neurodegenerative diseases.

Vanadium  /  Vanadyl N-(p-N,N-dimethylaminophenylcarbamoylmethyl)iminodiacetate (VO(p-dmada))  /  Neuroinflammation  /  Microglia  /  Proteomics  /  Peroxisome proliferator activated receptor gamma (PPARγ)
Zhijun He, Xiaoqian Li, Huajie Zhang, Xin Liu, Shuangxue Han, Anwar Abdurahman, Liming Shen, Xiubo Du, Nan Li, Xiaoda Yang, Qiong Liu. A novel vanadium complex VO(p-dmada) inhibits neuroinflammation induced by lipopolysaccharide[J]. Chinese Chemical Letters, 2023 , 34 (10) : 108236 - . DOI: 10.1016/j.cclet.2023.108236
Full Text
Less
Neuroinflammation mediated by overactivated glial cells is a common pathological feature of neurodegenerative diseases [1,2]. Microglia, acting as immune cells in the central nervous system, play a critical role in regulating the neurotoxicity caused by inflammatory response [3-5]. Under pathological conditions, microglia can be overactivated and in turn result in overproduction of many inflammatory mediators including nitric oxide (NO), prostaglandin E2 (PGE2), and pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) [6]. These inflammatory cytokines can collectively lead to eventful neurotoxicity and aggravated progress of neurodegenerative diseases [4]. Accordingly, the control of aberrant activation of microglia is regarded as a potentially powerful strategy for preventing neurodegenerative diseases.
Neuroinflammation can be induced by a range of pathogens, such as β-amyloid (Aβ), viruses and lipopolysaccharide (LPS) [7-9]. These pathogenic stimuli could activate nuclear factor-kappa B (NF-κB) signaling pathway both in vivo and in vitro [7-9]. NF-κB, a vital transcription factor that regulates inflammatory response, is sequestered in the cytoplasm via combining with inhibitory kappa B (IκB) in the resting microglia. LPS can activate the IκB kinase (IKK) which in turn phosphorylates IκB and leads to its ubiquitination and further degradation by the proteasome, and eventually results in translocation of NF-κB from cytoplasm to the nucleus. Once in the nucleus, NF-κB acts as a nuclear transcription factor to regulate the expression of inflammatory mediators including TNF-α, IL-6, IL-1β, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) [7,10]. Therefore, inactivation of NF-κB signaling is a promising strategy for treatment of neuroinflammation-based diseases.
Peroxisome proliferator activated receptor gamma (PPARγ), a vital ligand-activated nuclear transcription factor, plays a critical role in regulating energy balance, insulin sensitization, neuronal differentiation, and inflammation [11-14]. When activated, PPARγ immediately binds to the PPAR-response element and directly induces or represses transcription of downstream target genes [15]. Decreased expression of PPARγ has been observed in LPS-stimulated microglial cells and mice [16,17]. PPARγ activators have been found to regulate inflammatory response in several models of central nervous system (CNS) disorders [7,18]. Accumulated evidences showed that PPARγ activation can suppress the release of proinflammatory cytokines through the inhibition of NF-κB signaling [19]. Some vanadium compounds, such as bis(ethylmaltolato)oxidovanadium(IV) (BEOV), have been reported as PPARγ modulators and thus as potential agents for the treatment of diabetes and cerebral ischemia [20-22].
Metal ions are indispensable for living organism. Metal-based coordination compounds have attracted extensive attention for diagnosis and treatment of various diseases [22-25]. Vanadium, a biological trace element with some unique features, has also received a great deal of attention from the researchers in various areas including chemistry, biology, toxicology and pharmacology [26]. Vanadyl N-(p-N,N-dimethylaminophenylcarbamoylmethyl) iminodiacetate (VO(p-dmada)), a novel vanadium complex with low toxicity and high bioavailability, is synthesized from vanadyl sulfate and N,N-dimethyl-p-phenylenediamine in our laboratory (Fig. S1A in Supporting information). The p-H2dmada ligand and VO(p-dmada) complex were structurally characterized using Fourier transform infrared (FT-IR) and nuclear magnetic resonance (NMR) spectroscopies and mass spectrum (MS) (Figs. S1B-F in Supporting information). In a preliminary study, VO(p-dmada) showed better anti-diabetic effect than other vanadium compounds [27]. In this study, we endeavored to explore the effect of VO(p-dmada) on neuroinflammation. Thus, BV2 microglial cells were initially treated with VO(p-dmada) to find out its optimum concentration by CCK-8 assay. As shown in Fig. S2 (Supporting information), VO(p-dmada) did not display any cytotoxic effect on BV2 cells and LPS-induced BV2 cells at doses ranging from 0 to 10 µmol/L.
LPS is a common toxicant for microglial activation [9,28,29]. During neuroinflammatory processes, NO and PGE2, two critical proinflammatory mediators, are produced by activated microglia [30]. Thus, the suppression of NO and PGE2 emancipation in LPS-stimulated BV2 microglia were measured to evaluate the anti-inflammatory effects of VO(p-dmada). As shown in Fig. S3A (Supporting information), the levels of released NO and PGE2 in the culture medium were dramatically elevated after stimulation with LPS. Treatment with VO(p-dmada) significantly inhibited the excessive secretion of NO and PGE2 by LPS-stimulated BV2 microglia. Since the production of NO and PGE2 is regulated by iNOS and COX-2, respectively, inhibition of iNOS and COX-2 expression could be a primary strategy for decreasing inflammatory response [31]. Thus, the expression of iNOS and COX-2 were examined by Western blot and immunofluorescence analysis. The data in Figs. S3B-E and Fig. S4 (Supporting information) indicated that iNOS and COX-2 protein levels were dramatically decreased by VO(p-dmada) treatment. The mRNA level of iNOS was also decreased significantly by VO(p-dmada) treatment (Fig. S5A in Supporting information). Further investigation showed that VO(p-dmada) reduced the levels of NO, iNOS and COX-2 proteins in a time-dependent manner, when it was incubated with the cells for 4, 8, 16 and 24 h, respectively (Fig. S6 in Supporting information).
TNF-α, IL-12 and IL-6 were important pro-inflammatory cytokines released by activated immune cells [3,4,32,33]. Vanadium compounds have been reported to regulate the production of proinflammatory cytokines [7,21]. To ascertain whether VO(p-dmada) can affect the production of inflammatory cytokines, the levels of TNF-α, IL-12 and IL-6 were analyzed by ELISA. As shown in Fig. S3F (Supporting information), TNF-α, IL-6 and IL-12 levels were increased dramatically in the culture media of LPS-stimulated BV2 microglia when compared with unstimulated control, while VO(p-dmada) treatment obviously inhibited the secretion of inflammatory cytokines. These data suggest that VO(p-dmada) suppresses LPS-induced inflammatory responses via downregulating the expression of iNOS and COX-2 and inflammatory cytokines.
Overproduction of proinflammatory mediators in LPS-stimulated BV2 microglia was primarily regulated by NF-κB signaling pathway [34]. To further evaluate whether the anti-inflammatory effect of VO(p-dmada) was associated with NF-κB signaling pathway, the expression levels of IκB-α, p-IκB-α, p65 and p-p65 were analyzed by Western-blot in LPS-stimulated BV2 microglia. As shown in Figs. S3G and H (Supporting information), the phosphorylation levels of IκB-α and p65 were distinctly augmented in LPS-stimulated BV2 microglia compared with unstimulated control. Interestingly, VO(p-dmada) treatment significantly reduced the phosphorylation levels of these proteins. Immunofluorescent staining was used to reveal the cellular distribution of p65. The fluorescent images showed that VO(p-dmada) treatment markedly blocked NF-κB/p65 nuclear translocation in LPS-stimulated BV2 microglia (Figs. S3I and J in Supporting information). The mRNA level of p65 was also decreased significantly by VO(p-dmada) treatment (Fig. S5B in Supporting information). These results indicated that the inhibitory effects of VO(p-dmada) on LPS-induced TNF-α, IL-6 and IL-12 secretion came from the suppression of NF-κB signaling pathway.
We further investigated the effects of VO(p-dmada) on LPS-induced inflammatory responses in mice and the experimental procedures for mice treatment are illustrated in Fig. S7A (Supporting information). Whether the novel compound can pass through the blood-brain barrier (BBB) is a checkpoint for developing drug to treat brain diseases. In a previous study, we confirmed that BEOV was able to cross the BBB in APPswe/PS1E9 transgenic mice [35]. Similarly, we verified in the current study that VO(p-dmada) could also pass through the BBB and reach into the brain parenchyma (Figs. S7B and C in Supporting information). Ionized calcium binding adaptor molecule-1 (Iba-1) and glial fibrillary acidic protein (GFAP) are specifically expressed in the microglia and astroglia, respectively, and up-regulated upon stimulation of toxicants [36]. The expression levels of Iba-1 and GFAP were measured in the hippocampus by Western blot and immunofluorescence staining. We found that the protein levels of Iba-1 and GFAP were significantly increased in the LPS-stimulated group in hippocampal tissue when compared with those in control group. However, treatment with VO(p-dmada) significantly suppressed the levels of Iba-1 and GFAP (Figs. 1A-C and Fig. S8 in Supporting information). Furthermore, VO(p-dmada) significantly reduced the production of pro-inflammatory enzymes and cytokines including iNOS, COX-2, TNF-α and IL-6 in the brain and serum of LPS-treated mice (Figs. 1D-G). These findings support the speculation that VO(p-dmada) can pass through the BBB to exert anti-neuroinflammatory effects in brain.
To systematically investigate the proteins affected by VO(p-dmada) treatment, a quantitative proteomic analysis based on SWATH methodology was used to identify differentially expressed proteins (DEPs) in hippocampus. SWATH-MS analysis identified a total of 4006 quantitative proteins with 2825 quantitative proteins meeting the quality control requirements after QC correction. Among them, 76, 201, 44 and 31 proteins were identified as DEPs in LPS-induced vs. control groups (LPS/Ctrl), LPS + 0.1 mmol/kg VO(p-dmada) treated vs. LPS groups (Low/LPS), LPS + 0.2 mmol/kg VO(p-dmada) treated vs. LPS groups (High/LPS), and High/Low groups, respectively (Tables S2-S5 in Supporting information, Figs. 2A-D). Among the DEPs in LPS/Ctrl group, 66 proteins were up-regulated, and 10 proteins were down-regulated (Fig. 2A). Gene ontology (GO) analysis and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment were then performed to those DEPs (Fig. 2 and Fig. S9 in Supporting information). GO analysis showed that the biological processes (BPs) linked to DEPs of LPS/Ctrl groups were mainly enriched in the response and regulation to stress, vesicle-mediated transports, cell-cell signaling, secretion, neuron projection development and immune system process, etc. (Fig. 2E). KEGG pathway analysis showed that the majorities of DEPs were involved in endocytosis, metabolism, dopaminergic synapse and adrenergic signaling in cardiomyocytes, etc. (Fig. 2F). Interestingly, the results of the cluster analysis showed that the protein expression pattern of the LPS group remarkably different from those of the other three groups, while the two VO(p-dmada)-treated groups and the Ctrl group had similar pattern. Interestingly, the majority of DEPs up-regulated in LPS/Ctrl groups were down-regulated in two LPS+VO(p-dmada)/LPS groups (Fig. 2G). Among the DEPs in Low/LPS groups, 4 proteins were up-regulated and 197 proteins were down-regulated (Table S3 and Fig. 2B). Among the DEPs in High/LPS groups, 8 proteins were up-regulated and 36 proteins were down-regulated (Table S4 and Fig. 2C). GO analysis of BP, cellular component (CC) and molecular function (MF) and KEGG pathways enrichment of these proteins were shown in Figs. S10A-D and S11 (Supporting information). In addition, the GO-BP enrichment results of DEPs in High/LPS groups contained a part of the enriched terms for DEPs in Low/LPS groups (Fig. S10E in Supporting information). The Pathway Activation Strength (PAS) value was calculated for DEPs by omicsbean online tool. In the LPS/Ctrl groups, DEPs-activated processes included the responses to stress, oxygen-containing compound and immune system. The changes of these processes were reversed in a certain degree after VO(p-dmada) treatment (Fig. S12 in Supporting information). The protein-protein interactions (PPI) network further confirmed that the majority of DEPs in LPS/Ctrl, Low/LPS and High/LPS groups were enriched in the responses to stress, oxygen-containing compound and inflammation (Fig. S13 in Supporting information). Among them, transglutaminase 2 (Tgm2), heat shock protein 60 (Hspd1), Parkinson disease protein 7 homolog (Park7), 14-3-3 protein zeta/delta (Ywhaz), and peroxiredoxin 2 (Prdx2) were proteins closely associated with inflammatory response, which were identified as the key proteins of VO(p-dmada) treatment in LPS-induced mice (Fig. S13D). Those proteomic results further verified the beneficial effects of VO(p-dmada) on modulating neuroinflammatory reactions.
Transglutaminase 2 (TG2 or TGase 2, gene name: Tgm2) and heat shock protein 60 (Hsp60, gene name: Hspd1) are two proteins that play essential roles in regulating inflammatory response [37,38]. LPS could induce up-regulation of TG2 and Hsp60, leading to inflammatory cascade reactions [39,40]. To verify the results of proteomic study, Western blot analysis was performed for those two proteins. As shown in Figs. S14A and B (Supporting information), the levels of TG2 and Hsp60 were remarkably increased in the hippocampus of LPS-induced mice compared with the vehicle-treated control. Treatment with VO(p-dmada) significantly reduced TG2 and Hsp60 protein levels.
PPARγ, an important ligand-activated transcription factor, plays a critical role in regulating gene expression during several physiologic and pathological processes [41,42]. TG2 could control inflammation through PPARγ in cystic fibrosis epithelial cells [43]. Previous study reported that overexpression of Hsp60 significantly decreased PPARγ protein level and vanadium compounds were able to elevate PPARγ protein level in mouse insulinoma NIT-1 cells through regulating Hsp60 [20]. Here, we examined the effect of VO(p-dmada) on PPARγ expression in LPS-stimulated BV2 cells and BALB/c mice. As shown in Figs. S14C-H (Supporting information), LPS treatment significantly reduced PPARγ expression both in BV2 microglia and mice, while VO(p-dmada) effectively upregulated the protein level of PPARγ. These findings suggest that VO(p-dmada) is possible to indirectly increase the level of PPARγ through down-regulation of TG2 and Hsp60 expression.
Then, is it possible for VO(p-dmada) to act directly on PPARγ? To answer this question, we applied the softwares Autodock vina 1.1.2 and Free of Meastro 10.1 to mimic the binding of VO(p-dmada) and PPARγ molecules. The binding energy of VO(p-dmada) with PPARγ was calculated to be −8.2 kcal/mol, indicating a superior binding affinity between VO(p-dmada) (as a ligand) and PPARγ (as a receptor). As shown in Fig. 3, three hydrogen bonds formed between VO(p-dmada) and PPARγ at residues Arg288, Gly284 and Ser342, demonstrating that VO(p-dmada) can interact directly with PPARγ at high binding affinity and thus functions as a PPARγ agonist to regulate its activity.
Cumulative evidences have shown that activated PPARγ could inhibit NF-κB signaling pathway and in turn mitigated neuroinflammation both in vivo and in vitro [7,44]. Bisperoxovanadium and BEOV have been reported to increase PPARγ activity and inhibit inflammation [7,21]. In order to investigate the mechanism of VO(p-dmada) in regulating LPS-evoked neuroinflammation, BV2 microglia were treated with LPS, VO(p-dmada) and GW9662 (a general PPARγ inhibitor), simultaneously. As expected, the results showed that GW9662 remarkably impeded the effect of VO(p-dmada) on increasing the protein levels of PPARγ (Fig. S15 in Supporting information). The levels of released inflammatory mediators including TNFα, IL-6, IL-12, PGE2 and NO were also meausured using ELISA kit and Griess reagent. As shown in Fig. S16 (Supporting information), the inhibitory effect of VO(p-dmada) on inflammatory mediators was eliminated after adding GW9662. Moreover, the inhibition of PPARγ by GW9662 markedly restored the levels of iNOS and COX-2 that were reduced by VO(p-dmada) treatment (Figs. 4A and B, Fig. S17 in Supporting information). Further study on VO(p-dmada) in regulating NF-κB signaling pathway, the levels of IκB-α and p65 phosphorylation were detected. As shown in Figs. 4C and D, GW9662 also inhibited the down-regulating effect of VO(p-dmada) on these proteins. Taken together, these findings indicated that VO(p-dmada) treatment attenuated the LPS-stimulated neuroinflammation by inactivating NF-κB signaling via a PPARγ-dependent mechanism.
In summary, we demonstrated, for the first time, that VO(p-dmada) can attenuate proinflammatory mediator production and NF-κB signaling pathway activation in LPS-stimulated mice and BV2 microglia. The underlying mechanism of VO(p-dmada) in inhibiting inflammatory response is concluded and shown in Fig. S18 (Supporting information). VO(p-dmada) thus might be a promising candidate for treating neuroinflammation-based brain diseases.
Declaration of competing interest
Less
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments
Less
This study was financially supported by grants from the National Natural Science Foundation of China (No. 21877081), the China Postdoctoral Science Foundation (No. 2021M692210), Guangdong Provincial Key S&T Program (No. 2018B030336001), the Shenzhen Science and Technology Innovation Commission (No. JCYJ20200109110001818), and the Shenzhen-Hong Kong Institute of brain Science-Shenzhen Fundamental Research institutions (No. 2022SHIBS0003). We would like to thank the Instrumental Analysis Center of Shenzhen University and the Central Research Facilities of College of Life Sciences and Oceanography of Shenzhen University for the use of laser scanning confocal microscope.
Supplementary materials
Less
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2023.108236.
References
Less
[1]
B. Liu, J.S. Hong, J. Pharmacol. Exp. Ther. 304 (2003) 1-7.
[2]
C.K. Glass, K. Saijo, B. Winner, M.C. Marchetto, F.H. Gage, Cell 140 (2010) 918-934.
[3]
L. Yuan, S. Liu, X. Bai, et al., J. Neuroinflammation 13 (2016) 77.
[4]
M.L. Block, L. Zecca, J.S. Hong, Nat. Rev. Neurosci. 8 (2007) 57-69.
[5]
M. Prinz, S. Jung, J. Priller, Cell 179 (2019) 292-311.
[6]
J.A. Smith, A. Das, S.K. Ray, N.L. Banik, Brain Res. Bull. 87 (2012) 10-20.
[7]
Z. He, X. Li, S. Han, et al., Metallomics 13 (2021) mfab036.
[8]
S. Hong, W.A. Banks, Brain Behav. Immun. 45 (2015) 1-12.
[9]
P. Cao, C. Chen, A. Liu, Q. et al., Neuron 109 (2021) 2573-2589.e9.
[10]
A. Hoffmann, A. Levchenko, M.L. Scott, D. Baltimore, Science 298 (2002) 1241-1245.
[11]
K.K. Ryan, B. Li, B.E. Grayson, et al., Nat. Med. 17 (2011) 623-626.
[12]
C. Janani, B.D. Ranjitha Kumari, Diabetes Metab. Syndr. 9 (2015) 46-50.
[13]
J. Ji, T.F. Xue, X.D. Guo, et al., Aging Cell 17 (2018) e12774.
[14]
M. Kawai, C.J. Rosen, Nat. Rev. Endocrinol. 6 (2010) 629-636.
[15]
A. Dharap, C. Pokrzywa, S. Murali, et al., J. Neurochem. 135 (2015) 139-146.
[16]
L. Zhang, J. Gao, P. Tang, et al., Int. Immunopharmacol. 63 (2018) 9-13.
[17]
Y. Liang, T. Shen, Q. Ming, et al., Int. Immunopharmacol. 62 (2018) 309-312.
[18]
E. Medrano-Jiménez, I. Jiménez-Ferrer Carrillo, M. Pedraza-Escalona, et al., J. Neuroinflammation 16 (2019) 143.
[19]
Q. Li, Z. Tian, M. Wang, et al., Int. Immunopharmacol. 66 (2019) 309-316.
[20]
P. Zhao, X. Yang, Metallomics 5 (2013) 836-843.
[21]
L.L. Mao, D.L. Hao, X.W. Mao, et al., Neurosci. Lett. 602 (2015) 120-125.
[22]
B. Feng, Y. Dong, B. Shang, et al., Adv. Funct. Mater. 32 (2022) 1-14.
[23]
L.N. Xie, Z.D. Luo, Z.N. Zhao, T.F. Chen, J. Med. Chem. 60 (2017) 202-214.
[24]
J.J. Li, H.J. Luo, X.Q. Zhu, et al., Chin. Chem. Lett. 33 (2022) 788-792.
[25]
M. Chen, X.T. Huang, J. Lai, et al., Chin. Chem. Lett. 32 (2021) 158-161.
[26]
A. Ścibior, Ł. Pietrzyk, Z. Plewa, et al., J. Trace. Elem. Med. Biol. 61 (2020) 126508.
[27]
X. Niu, J. Yang, X.D. Yang, J. Inorg. Biochem. 177 (2017) 291-299.
[28]
C.M. Sandiego, J.D. Gallezot, B. Pittman, et al., Proc. Natl. Acad. Sci. U. S. A. 112 (2015) 12468-12473.
[29]
J. Jiang, B. Tang, L. Wang, et al., Brain Behav. Immun. 99 (2022) 53-69.
[30]
F. Aloisi, Glia 36 (2001) 165-179.
[31]
Y. Fang, L. Yang, J. He, Biomed. Pharmacother. 143 (2021) 112104.
[32]
Y.Y. Song, C.M. Dong, Chin. Chem. Lett. 33 (2022) 4084-4088.
[33]
B. Becher, S. Spath, J. Nat. Rev. Immunol. 17 (2017) 49-59.
[34]
B. Zhang, W. Lian, J. Zhao, et al., Oxid. Med. Cell. Longev. 2021 (2021) 6521146.
[35]
Z. He, M. Wang, Q. Zhao, et al., J. Inorg. Biochem. 208 (2020) 111073.
[36]
D.M. Norden, P.J. Trojanowski, E. Villanueva, E. Navarro, J.P. Godbout, Glia 64 (2016) 300-316.
[37]
Q. Huang, W. Gao, H. Mu, et al., Oxid. Med. Cell. Longev. 2020 (2020) 8706898.
[38]
J. Lee, Y.S. Kim, D.H. Choi, et al., J. Biol. Chem. 279 (2004) 53725-53735.
[39]
T. Su, X.Y. Qin, Y. Furutani, et al., Anal Biochem. 597 (2020) 113654.
[40]
Y. Zhang, X. Qi, X. Chen, et al., Food Funct. 12 (2021) 4392-4401.
[41]
Z. Liao, J. Dong, W. Wu, et al., Respir. Res. 13 (2012) 110.
[42]
X.H. Li, Y.Y. Deng, F. Li, et al., Int. J. Mol. Med. 38 (2016) 1152-1160.
[43]
L. Maiuri, A. Luciani, I. Giardino, et al., J. Immunol. 180 (2008) 7697-7705.
[44]
Y. Hou, F. Moreau, K. Chadee, Nat. Commun. 3 (2012) 1300.
Appendix
Less
Year 2023 volume 34 Issue 10
PDF
53
30
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.cclet.2023.108236
  • Receive Date：2022-11-14
  • Online Date：2025-11-21
  • Published：2023-10-15
Article Data
Affiliations
History
  • Received：2022-11-14
  • Revised：2023-02-11
  • Accepted：2023-02-15
Affiliations
    a Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518055, China
    b National R&D Center for Se-rich Agricultural Products Processing, Hubei Engineering Research Center for Deep Processing of Green Se-rich Agricultural Products, School of Modern Industry for Selenium Science and Engineering, Wuhan Polytechnic University, Wuhan 430023, China
    c Shenzhen Bay Laboratory, Shenzhen 518055, China
    d State Key Laboratories of Natural and Biomimetic Drugs, Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
    e Department of Pharmacy, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China
    f Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen 518055, China
References
Share
https://castjournals.cast.org.cn/joweb/ccl/EN/10.1016/j.cclet.2023.108236
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House